Evolus Raises 2028 Revenue Targets as Toxin Market Stabilizes

Evolus, a company specializing in aesthetic medicine, announced during a recent conference that it expects the toxin market to stabilize, alongside its product, Evolysse, gaining traction. This positive outlook on revenue targets for 2028 signals a potential rebound in the aesthetics sector, impacting the company's stock performance. Key indicators from the conference highlighted increases in consumer demand and a projected revenue growth rate of over 20%. The news may lead to enhanced investor confidence, positively influencing market sentiment around beauty and wellness stocks.